Literature DB >> 22384544

[Effects of xuezhikang at different doses on patients suffering from acute coronary syndrome after percutaneous coronary intervention].

Fang-yong Jiang1, Li-ping Sun, Jin Yang.   

Abstract

OBJECTIVE: To study the effects Xuezhikang (XZK) at different doses on inflammatory factors and blood lipids of patients suffering from acute coronary syndrome (ACS) after percutaneous coronary intervention (PCI) and to discuss their safety.
METHODS: Eighty ACS in patients receiving selective PCI treatment were randomly assigned to two groups, 40 cases in the normal dose group and 40 cases in the large dose XZK group. Besides routine therapy, all patients took XZK at the daily dose of 1.2 and 0. 6 g, twice daily. They started XZK from the very day of PCI operation. The therapeutic course for all was more than 8 weeks. The levels of high sensitivity C reactive protein (hs-CRP) and matrix metalloproteinase-9 (MMP-9) were detected in the two groups 1 week, 4 and 8 weeks after operation. The levels of TC, TG, HDL-C, LDL-C, changes of liver and renal functions were observed. The correlation between blood lipids and inflammatory factors were analyzed. The adverse reaction was recorded.
RESULTS: Compared with before medication, the serum levels of hs-CRP and MMP-9 decreased in the two groups 1 week, 4 and 8 weeks after operation, with statistical difference shown in the levels at the 8th week (P < 0.05). The decrease was more obvious in the large dose XZK group (P < 0.05). The LDL-C level obviously decreased in the two groups 4 and 8 weeks after operation (P < 0.05). The decrease was more obvious in the large dose XZK group at the 8th week (P < 0.05). The levels of hs-CRP and MMP-9 were positively correlated with the decrease degree of LDL-C in the large dose XZK group at the 8th week (r = 0.828, 0.922, P < 0.05). There was no significant difference in the occurrence of adverse reaction, hepatic or renal functions between the two groups.
CONCLUSIONS: XZK could lower the serum levels of hs-CRP, MMP-9, and LDL-C. More obvious effects were obtained in the large dose XZK group. The decrease degree of inflammatory factors was correlated with the decrease extent of blood lipids.

Entities:  

Mesh:

Substances:

Year:  2011        PMID: 22384544

Source DB:  PubMed          Journal:  Zhongguo Zhong Xi Yi Jie He Za Zhi        ISSN: 1003-5370


  3 in total

1.  Hypertensive vascular remodeling was inhibited by Xuezhikang through the regulation of Fibulin-3 and MMPs in spontaneously hypertensive rats.

Authors:  Zhong-Wei Lin; Zhuo Wang; Gui-Ping Zhu; Bo-Wei Li; Wen-Lin Xie; Ding-Cheng Xiang
Journal:  Int J Clin Exp Med       Date:  2015-02-15

2.  Effect on LDL-cholesterol of a large dose of a dietary supplement with plant extracts in subjects with untreated moderate hypercholesterolaemia: a randomised, double-blind, placebo-controlled study.

Authors:  Emmanuel Barrat; Yassine Zaïr; Pascal Sirvent; Patrice Chauveau; Corinne Maudet; Béatrice Housez; Elodie Derbord; Jean-François Lescuyer; Jean-Marie Bard; Murielle Cazaubiel; Sébastien L Peltier
Journal:  Eur J Nutr       Date:  2012-12-25       Impact factor: 5.614

3.  Novel findings in relation to multiple anti-atherosclerotic effects of XueZhiKang in humans.

Authors:  Rui-Xia Xu; Yan Zhang; Yuan-Lin Guo; Chun-Yan Ma; Yu-Hong Yao; Sha Li; Xiao-Lin Li; Ping Qing; Ying Gao; Na-Qiong Wu; Cheng-Gang Zhu; Geng Liu; Qian Dong; Jing Sun; Jian-Jun Li
Journal:  Chronic Dis Transl Med       Date:  2017-11-14
  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.